|
1
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005.
View Article : Google Scholar
|
|
2
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Park YN: Update on precursor and early
lesions of hepatocellular carcinomas. Arch Pathol Lab Med.
135:704–715. 2011.PubMed/NCBI
|
|
4
|
Theise ND, Curado MP, Franceschi S,
Hytiroglou P, Kudo M, Park YN, Sakamoto M, Torbenson M and Wee A:
Hepatocellular carcinoma. WHO Classification Of Tumours Of The
Digestive System. Bosman FT, Carneiro F, Hruban RH and Theise ND:
4th edition. IARC Press; Lyon: pp. 205–216. 2010
|
|
5
|
Durnez A, Verslype C, Nevens F, Fevery J,
Aerts R, Pirenne J, Lesaffre E, Libbrecht L, Desmet V and Roskams
T: The clinicopathological and prognostic relevance of cytokeratin
7 and 19 expression in hepatocellular carcinoma. A possible
progenitor cell origin. Histopathology. 49:138–151. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhuang PY, Zhang JB, Zhu XD, Zhang W, Wu
WZ, Tan YS, Hou J, Tang ZY, Qin LX and Sun HC: Two pathologic types
of hepatocellular carcinoma with lymph node metastasis with
distinct prognosis on the basis of CK19 expression in tumor.
Cancer. 112:2740–2748. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kim H, Choi GH, Na DC, Ahn EY, Kim GI, Lee
JE, Cho JY, Yoo JE, Choi JS and Park YN: Human hepatocellular
carcinomas with ‘Stemness’-related marker expression: keratin 19
expression and a poor prognosis. Hepatology. 54:1707–1717.
2011.
|
|
8
|
Tsuchiya K, Komuta M, Yasui Y, Tamaki N,
Hosokawa T, Ueda K, Kuzuya T, Itakura J, Nakanishi H, Takahashi Y,
Kurosaki M, et al: Expression of keratin 19 is related to high
recurrence of hepatocellular carcinoma after radiofrequency
ablation. Oncology. 80:278–288. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yang XR, Xu Y, Yu B, Zhou J, Qiu SJ, Shi
GM, Zhang BH, Wu WZ, Shi YH, Wu B, Yang GH, Ji Y and Fan J: High
expression levels of putative hepatic stem/progenitor cell
biomarkers related to tumour angiogenesis and poor prognosis of
hepatocellular carcinoma. Gut. 59:953–962. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Andersen JB, Loi R, Perra A, Factor VM,
Ledda-Columbano GM, Columbano A and Thorgeirsson SS:
Progenitor-derived hepatocellular carcinoma model in the rat.
Hepatology. 51:1401–1409. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Edge SB, Byrd DR, Compton CC, Fritz AG,
Greene FL and Trotti A: AJCC Cancer Staging Manual. 7th edition.
Springer; New York: 2010
|
|
12
|
Choi HN, Bae JS, Jamiyandorj U, Noh SJ,
Park HS, Jang KY, Chung MJ, Kang MJ, Lee DG and Moon WS: Expression
and role of SIRT1 in hepatocellular carcinoma. Oncol Rep.
26:503–510. 2011.PubMed/NCBI
|
|
13
|
Moll R, Franke WW, Schiller DL, Geiger B
and Krepler R: The catalog of human cytokeratins: patterns of
expression in normal epithelia, tumors and cultured cells. Cell.
31:11–24. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lai YS, Thung SN, Gerber MA, Chen ML and
Schaffner F: Expression of cytokeratins in normal and diseased
livers and in primary liver carcinomas. Arch Pathol Lab Med.
113:134–138. 1989.PubMed/NCBI
|
|
15
|
Johnson DE, Herndier BG, Medeiros LJ,
Warnke RA and Rouse RV: The diagnostic utility of the keratin
profiles of hepatocellular carcinoma and cholangiocarcinoma. Am J
Surg Pathol. 12:187–197. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Libbrecht L, Desmet V, Van Damme B and
Roskams T: The immunohistochemical phenotype of dysplastic foci in
human liver: correlation with putative progenitor cells. J Hepatol.
33:76–84. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Van Eyken P, Sciot R, Paterson A, Callea
F, Kew MC and Desmet VJ: Cytokeratin expression in hepatocellular
carcinoma: an immunohistochemical study. Hum Pathol. 19:562–568.
1988.PubMed/NCBI
|
|
18
|
Ding SJ, Li Y, Tan YX, Jiang MR, Tian B,
Liu YK, Shao XX, Ye SL, Wu JR, Zeng R, Wang HY, Tang ZY and Xia QC:
From proteomic analysis to clinical significance: overexpression of
cytokeratin 19 correlates with hepatocellular carcinoma metastasis.
Mol Cell Proteomics. 3:73–81. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Limaye PB, Bowen WC, Orr AV, Luo J, Tseng
GC and Michalopoulos GK: Mechanisms of hepatocyte growth
factor-mediated and epidermal growth factor-mediated signaling in
transdifferentiation of rat hepatocytes to biliary epithelium.
Hepatology. 47:1702–1713. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Nishikawa Y, Doi Y, Watanabe H, Tokairin
T, Omori Y, Su M, Yoshioka T and Enomoto K: Transdifferentiation of
mature rat hepatocytes into bile duct-like cells in vitro. Am J
Pathol. 166:1077–1088. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yoneda N, Sato Y, Kitao A, Ikeda H,
Sawada-Kitamura S, Miyakoshi M, Harada K, Sasaki M, Matsui O and
Nakanuma Y: Epidermal growth factor induces cytokeratin 19
expression accompanied by increased growth abilities in human
hepatocellular carcinoma. Lab Invest. 91:262–272. 2011. View Article : Google Scholar
|
|
22
|
Zen C, Zen Y, Mitry RR, Corbeil D,
Karbanová J, O’Grady J, Karani J, Kane P, Heaton N, Portmann BC and
Quaglia A: Mixed phenotype hepatocellular carcinoma after
transarterial chemoembolization and liver transplantation. Liver
Transpl. 17:943–954. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ravaioli M, Grazi GL, Ercolani G,
Fiorentino M, Cescon M, Golfieri R, Trevisani F, Grigioni WF,
Bolondi L and Pinna AD: Partial necrosis on hepatocellular
carcinoma nodules facilitates tumor recurrence after liver
transplantation. Transplantation. 78:1780–1786. 2004. View Article : Google Scholar
|
|
24
|
Nishihara Y, Aishima S, Kuroda Y, Iguchi
T, Taguchi K, Asayama Y, Taketomi A, Kinukawa N, Honda H and
Tsuneyoshi M: Biliary phenotype of hepatocellular carcinoma after
preoperative transcatheter arterial chemoembolization. J
Gastroenterol Hepatol. 23:1860–1868. 2008. View Article : Google Scholar
|
|
25
|
Shackleton M, Quintana E, Fearon ER and
Morrison SJ: Heterogeneity in cancer: cancer stem cells versus
clonal evolution. Cell. 138:822–829. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bomken S, Fiser K, Heidenreich O and
Vormoor J: Understanding the cancer stem cell. Br J Cancer.
103:439–445. 2010. View Article : Google Scholar
|
|
27
|
Aishima S, Nishihara Y, Kuroda Y, Taguchi
K, Iguchi T, Taketomi A, Maehara Y and Tsuneyoshi M: Histologic
characteristics and prognostic significance in small hepatocellular
carcinoma with biliary differentiation: subdivision and comparison
with ordinary hepatocellular carcinoma. Am J Surg Pathol.
31:783–91. 2007. View Article : Google Scholar
|
|
28
|
Lu XY, Xi T, Lau WY, Dong H, Zhu Z, Shen
F, Wu MC and Cong WM: Hepatocellular carcinoma expressing
cholangiocyte phenotype is a novel subtype with highly aggressive
behavior. Ann Surg Oncol. 18:2210–2217. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yuan RH, Jeng YM, Hu RH, Lai PL, Lee PH,
Cheng CC and Hsu HC: Role of p53 and β-catenin mutations in
conjunction with CK19 expression on early tumor recurrence and
prognosis of hepatocellular carcinoma. J Gastrointest Surg.
15:321–329. 2011.
|
|
30
|
Simon R and Sauter G: Tissue microarrays
for miniaturized high-throughput molecular profiling of tumors. Exp
Hematol. 30:1365–1372. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Uenishi T, Kubo S, Yamamoto T, Shuto T,
Ogawa M, Tanaka H, Tanaka S, Kaneda K and Hirohashi K: Cytokeratin
19 expression in hepatocellular carcinoma predicts early
postoperative recurrence. Cancer Sci. 94:851–857. 2003. View Article : Google Scholar : PubMed/NCBI
|
